FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
This article was originally published in The Tan Sheet
Executive Summary
The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.
You may also be interested in...
US Appropriators Question FDA’s OTC Switch Process Overhaul, Homeopathic Market Oversight
Appropriations Committee’s report with Agriculture, Rural Development, FDA and Related Agencies FY2021 budget bill also reiterated concern about adding acetaminophen dosing information for children to OTC monograph. But its mentions of FDA initiative to expand ingredients available OTC and homeopathic market oversight were firsts.
Room For Innovative Switches Could Lurk In Existing FDA Framework
When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.
Room For Innovative Switches Could Lurk In Existing FDA Framework
When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.